PDS Biotech Secures $22.55M PIPE Led by Dr. Patrick Soon-Shiong
Event summary
- PDS Biotech raises up to $22.55M in PIPE led by NantWorks' Dr. Patrick Soon-Shiong.
- Dr. Soon-Shiong to join PDS Biotech’s board of directors.
- Funding to advance PDS0301 immunocytokine into late-stage clinical trials.
- NantWorks gains exclusive negotiation rights for PDS0101 license.
- Initial closing expected September 11, 2026.
The big picture
This funding round positions PDS Biotech to accelerate its lead immunocytokine, PDS0301, into pivotal trials for solid tumors, an area with significant unmet needs. Dr. Soon-Shiong’s involvement brings both capital and expertise in immunocytokine development, potentially elevating PDS Biotech’s profile in the competitive oncology space. The deal underscores the growing interest in targeted immunotherapies for difficult-to-treat cancers.
What we're watching
- Clinical Trial Momentum
- Whether PDS0301 can sustain its promising Phase 2 results in late-stage trials.
- Strategic Partnerships
- The pace at which NantWorks advances the PDS0101 license negotiation.
- Governance Impact
- How Dr. Soon-Shiong’s involvement will influence PDS Biotech’s strategic direction.
Related topics